xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
NTSB Leads Investigation Into Ryanair Boeing 737 Engine Failure Over Greece 
Volvo Cars Q2 Profit Falls as Automaker Bets on EX60 EV to Drive Recovery 
SpaceX Eyes Pentagon AI Deal as Cloud Pricing Strategy Pressures CoreWeave 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
GameStop Raises eBay Stake to 9.8% as Ryan Cohen Pushes $56 Billion Takeover Bid 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Seven & i Eyes Żabka Stake in Major European Expansion Push 
Illumina Inc. is selling its cancer test developer, Grail, following its series of antitrust conflicts. The company is a known maker of gene-sequencing machines, and on Sunday, Dec. 17, it revealed its decision to divest this unit, which it bought in 2021 for $7.1 billion.
According to The New York Times, Illumina's move to divest its Grail unit came two days after the company recently lost in a court battle. It made an appeal, but the federal court largely sided with the Federal Trade Commission when it upheld the antitrust regulator's ruling that Illumina must sell its Grail on antitrust grounds.
Obstruction in Europe
It was reported that Illumina's deal for Grail was also not cleared in Europe, and it has, in fact, faced a roadblock there, too. In September last year, the EU said it would block the acquisition. The company publicly admitted that it had been unsuccessful with its appeals for the Grail deal, and this has led to the decision to divest the start-up.
At any rate, the company's troubles started when it went ahead and purchased the cancer test developer despite the complaint from the U.S. FTC. The commission argued that the buyout would reduce innovation in the American market as well as increase prices.
Execution of Illumina's GRAIL's Sale
The biotechnology company, headquartered in San Diego, California, said that its sale of GRAIL is set to be executed via a third-party or capital markets transaction that is in line with the European Commission's (EU) divestiture order. Illumina aims to finalize the terms of the deal by the end of the second quarter of 2024.
"We are committed to an expeditious divestiture of GRAIL in a manner that allows its technology to continue benefitting patients," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "The management team and I continue to focus on our core business and supporting our customers. I am confident in Illumina's opportunities and our long-term success."
Photo by: Illumina Press Release
